Page last updated: 2024-11-06

naftifine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Naftifine is an antifungal medication that is used to treat a variety of fungal infections, including athlete's foot, ringworm, and jock itch. It is a synthetically produced compound that is available in a variety of topical formulations, including creams, lotions, and gels. Naftifine works by inhibiting the growth of fungi by interfering with the synthesis of ergosterol, a vital component of fungal cell membranes. The compound's importance stems from its effectiveness in treating a wide range of fungal infections and its generally good safety profile. Naftifine is studied to further understand its efficacy and safety, investigate potential alternative formulations, and explore its potential use in treating other fungal infections.'

naftifine: allylamine der; RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47641
CHEMBL ID626
CHEBI ID7451
CHEBI ID93305
SCHEMBL ID49141
SCHEMBL ID3692459
MeSH IDM0093247

Synonyms (62)

Synonym
BRD-K74141488-003-03-9
aw-105-843
naftifin
BSPBIO_001046
PRESTWICK3_001063
NCGC00179332-01
n-methyl-n-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(e), hydrochloride
(e)-n-methyl-n-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine
sn 105-843
BPBIO1_001152
PRESTWICK2_001063
AB00514711
65472-88-0
C08071
naftifine
naftifine [inn:ban]
naftifinum [inn-latin]
(e)-n-cinnamyl-n-methyl-1-naphthylmethylamin
(e)-n-cinnamyl-n-methyl-1-naphthalenemethylamine
naftifina [inn-spanish]
1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, (e)-
(e)-n-cinnamyl-n-methyl-1-naphthalinmethylamin
naft-500
CHEMBL626 ,
chebi:7451 ,
(e)-n-methyl-n-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
naftifine (inn)
D08245
methyl-naphthalen-1-ylmethyl-((e)-3-phenyl-allyl)-amine
bdbm50170647
methyl-naphthalen-1-ylmethyl-(3-phenyl-allyl)-amine
naftifinum
naftifina
4fb1ton47a ,
unii-4fb1ton47a
naftifine [mi]
naftifine [who-dd]
naftifine [inn]
naftifine [vandf]
BRD-K43813806-003-01-0
AKOS025310693
STL483692
(2e)-n-methyl-n-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
SCHEMBL49141
OZGNYLLQHRPOBR-DHZHZOJOSA-N
SCHEMBL3692459
DTXSID6048545 ,
trans-n-cinnamyl-n-methyl-(1-naphthylmethyl)amine
(2e)-n-methyl-n-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine
AC-22577
AB00514711_08
AB00514711_07
CHEBI:93305
Q413586
A934003
EN300-18563888
methyl[(naphthalen-1-yl)methyl](3-phenylprop-2-en-1-yl)amine
1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, (z)-
dtxcid6028101
naftifinum (inn-latin)
naftifina (inn-spanish)
d01ae22

Research Excerpts

Overview

Naftifine is a synthetic allylamine antifungal first reported in 1974. In 1985 it became the first commercially available allylamin. Naftifine hydrochloride is used to treat tinea corporis. It has shown clinically significant anti-bacterial and anti-inflammatory effects.

ExcerptReferenceRelevance
"Naftifine is a synthetic allylamine antifungal first reported in 1974 and in 1985 became the first commercially available allylamine."( Naftifine: A Topical Allylamine for Superficial Dermatophytosis.
Madhu, R; Shah, B; Shirsat, AB; Trailokya, AA, 2023
)
3.07
"Naftifine hydrochloride is a topical antifungal of the allylamine class, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects."( Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials.
Fleischer, AB; Hardas, B; Kircik, L; Olayinka, B; Parish, LC; Plaum, S; Stein Gold, LF; Verma, A; Vlahovic, T, 2013
)
1.42
"Naftifine hydrochloride is a topical antifungal of the allylamine class, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects."( An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis.
Fleischer, AB; Olayinka, B; Verma, A, 2015
)
1.37
"Naftifine hydrochloride is a topical antifungal of the allylamine class used to treat tinea corporis, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects.
"
( Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.
Dhawan, S; Dobrowski, D; Gold, M; Kuligowski, M; Verma, A, 2016
)
1.47
"Naftifine (NF) is an antifungal drug poorly soluble in basic aqueous solutions. "( Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state.
Martín, C; Martínez-Ohárriz, MC; Sánchez, M; Uzqueda, M; Vélaz, I; Zornoza, A, 2006
)
2.05
"Naftifine is a topical allylamine that is effective and safe in the management of superficial dermatomycoses. "( Naftifine: a review.
Cooper, EA; Gupta, AK; Ryder, JE,
)
3.02
"Naftifine is an allylamine derivative for topical administration with a mechanism of action distinct from that of other classes of antifungal agents. "( Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses.
Brogden, RN; Monk, JP, 1991
)
3.17
"Naftifine is a new antifungal agent derived from naphtalenemethane amine and highly active in vitro against dermatophytes. "( [In vitro action of a new antifungal agent, naftifine, on dermatophytes].
Buffard, Y; Ferrari, H; Gallucci, V; Goudard, M; Regli, P, 1985
)
1.97

Effects

Naftifine has been developed as an agent for the topical treatment of dermatomycoses. SF 86-327 is the first orally applicable antifungal agent with a primarily fungicidal mode of action.

ExcerptReferenceRelevance
"Naftifine also has demonstrated anti-inflammatory properties such as a reduction in superoxide production and a reduction in polymorphonuclear leukocyte chemotaxis/endothelial adhesion."( Naftifine: a review.
Cooper, EA; Gupta, AK; Ryder, JE,
)
2.3
"Naftifine has been developed as an agent for the topical treatment of dermatomycoses, while SF 86-327 is under development in both topical and oral formulations, being the first orally applicable antifungal agent with a primarily fungicidal mode of action."( Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents.
Ganzinger, U; Petranyi, G; Stephen, A; Stutz, A, 1986
)
0.99

Treatment

Treatment with naftifine gel 2% applied once daily for two weeks is well-tolerated and is effective in treating both interdigital-type and moccasin-type tinea pedis.

ExcerptReferenceRelevance
"Treatment with naftifine gel 2% applied once daily for two weeks is well-tolerated and is effective in treating both interdigital-type and moccasin-type tinea pedis. "( Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials.
Fleischer, AB; Hardas, B; Kircik, L; Olayinka, B; Parish, LC; Plaum, S; Stein Gold, LF; Verma, A; Vlahovic, T, 2013
)
1.05
"Treatment with naftifine cream 2% applied once daily for two weeks was well-tolerated and was effective in treating tinea corporis in children. "( Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.
Dhawan, S; Dobrowski, D; Gold, M; Kuligowski, M; Verma, A, 2016
)
1.1

Toxicity

Naftifine 2% gel was efficacious and safe for the treatment of mild to moderate interdigital tinea pedis. Safety was evaluated by adverse events (AE) and laboratory values in 231 subjects.

ExcerptReferenceRelevance
" Adverse effects were minimal and included mild peeling in two patients and mild fissuring with transient fingertip numbness in one patient."( Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers.
Cohen, JL; Hochman, LG; Holwell, JE; Meyerson, MS; Pappert, AS; Scher, RK, 1993
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Safety was assessed by adverse events and changes from baseline in clinical status and laboratory studies."( A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris.
Avakian, E; Fleischer, AB; Hardas, B; Olayinka, B; Pappert, EJ; Parish, JL; Parish, LC; Plaum, S; Routh, HB, 2011
)
0.59
" Safety was evaluated by adverse events (AE) and laboratory values in 707 subjects."( A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.
Avakian, EV; Fleischer, AB; Hardas, B; Parish, JL; Parish, LC; Plaum, S; Routh, HB, 2011
)
0.6
"Topical NAFT-2 for two weeks is safe and provides significantly superior antifungal treatment than vehicle in tinea pedis subjects."( A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.
Avakian, EV; Fleischer, AB; Hardas, B; Parish, JL; Parish, LC; Plaum, S; Routh, HB, 2011
)
0.6
" Safety was evaluated by adverse events (AE) and laboratory values in 1714 subjects (n=1143, naftifine; n=571, vehicle)."( Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials.
Fleischer, AB; Hardas, B; Kircik, L; Olayinka, B; Parish, LC; Plaum, S; Stein Gold, LF; Verma, A; Vlahovic, T, 2013
)
0.92
" Treatment related adverse events were minimal."( Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials.
Fleischer, AB; Hardas, B; Kircik, L; Olayinka, B; Parish, LC; Plaum, S; Stein Gold, LF; Verma, A; Vlahovic, T, 2013
)
0.7
" Safety was evaluated by adverse events (AE) and laboratory values in 231 subjects (n=116, naftifine; n=115, vehicle)."( Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.
Dhawan, S; Dobrowski, D; Gold, M; Kuligowski, M; Verma, A, 2016
)
0.97
" Treatment related adverse events were minimal."( Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.
Dhawan, S; Dobrowski, D; Gold, M; Kuligowski, M; Verma, A, 2016
)
0.74
"Naftifine 2% gel was efficacious and safe for the treatment of mild to moderate interdigital tinea pedis."( Efficacy and Safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Pedis: A Phase III Randomised, Double-Blind, Parallel-Group, Active-Controlled Study in Indian Adult Patients.
Bandi, MR; Devireddy, SR; Halder, S; Kothiwala, RK; Panapakam, M; Rajamma, A; Sahu, S; Sankerneni, A; Sinha, SD; Sriramadasu, SC; Vattipalli, R; Vemireddy, VNR, 2023
)
2.66

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic blood and urine samples were collected at various time points throughout the study."( An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis.
Fleischer, AB; Olayinka, B; Verma, A, 2015
)
0.65

Bioavailability

ExcerptReferenceRelevance
" When given orally, terbinafine is well absorbed and rapidly and extensively distributed to the skin and sebum in concentrations that exceed the minimum inhibitory concentrations of these organisms by several orders of magnitude."( Pharmacology of the allylamines.
Birnbaum, JE, 1990
)
0.28
" Furthermore, it provides a highly efficient cellular uptake and excellent bioavailability in vitro and enables a deep penetration during transfollicular delivery in vivo."( Transdermal platform for the delivery of the antifungal drug naftifine hydrochloride based on porous vaterite particles.
Abalymov, A; Atkin, V; Gusliakova, O; Kozlova, A; Lengert, E; Morrison, A; Nechaeva, O; Svenskaya, Y; Tuchin, V; Verkhovskii, R, 2021
)
0.86

Dosage Studied

ExcerptRelevanceReference
" Twelve subjects were dosed daily (6 with naftifine cream, 2% and 6 with naftifine gel, 2%)."( Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%.
Fleischer, AB; Hardas, B; Olayinka, B; Plaum, S; Verma, A, 2013
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.14.13.132 (squalene monooxygenase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of squalene monooxygenase (EC 1.14.13.132).
sterol biosynthesis inhibitorAny compound that inhibits the biosynthesis of any sterol.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
allylamine antifungal drugAn organonitrogen compound that contains an amino group that is attached to a carbon which is itself attached to an olefinic carbon and which has been used as an antifungal drug.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi0.31000.00000.90487.1500AID239296
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki1.50000.00040.54906.7000AID239597
Squalene monooxygenaseCandida albicans SC5314IC50 (µMol)0.31700.31700.31700.3170AID1888277
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.88000.00000.490110.0000AID239347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (161)

Assay IDTitleYearJournalArticle
AID1742126Antifungal activity against Candida albicans assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID47891In vitro antifungal activity against Candida parapsilosis 391995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1728460Antifungal activity against Candida tropicalis ATCC 1369 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888308Antifungal activity against fluconazole resistant Candida albicans strain 901 assessed as fungal growth inhibition measured after 72 hrs in presence of miconazole by CLSI protocol based liquid medium dilution method
AID1728521Inhibition of Candida albicans ATCC SC5314 SE incubated for 30 mins by spectrophotometric method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1728464Antifungal activity against fluconazole-resistant Candida albicans 632 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1728468Antifungal activity against Candida albicans ATCC SC5314 assessed as reduction in cell division at 10 nM/mL by polarizing microscopy2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID70077In vitro minimum inhibitory concentration (MIC) against isolates of Epidermophyton floccosum in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1742150Inhibition of SE in Candida albicans ATCC SC5314 assessed as ergosterol level at 4 ug/ml incubated for 16 hrs by LC/MS analysis (Rvb = 79.43 %)2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID48065Antifungal activity was measured against Candida parapsilosis.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1658352Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring ergosterol content at 4 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 96.7%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1818292Inhibition of SE in Candida albicans ATCC SC5314 measured after 30 mins by HPLC analysis
AID1888274Antifungal activity against Candida albicans ATCC SC5314 assessed as change in lanosterol level at 4 ug/ml incubated for 48 hrs by LC-MS analysis (Rvb = 3.7%)
AID1742127Antifungal activity against Candida krusei assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1818289Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as lanosterol level incubated for 48 hrs by LC/MS analysis (Rvb = 1.2 %)
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1728497Inhibition of SE in Candida albicans ATCC SC5314 assessed as squalene level at 0.5 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1818280Induction of apoptosis against Candida albicans ATCC SC5314 assessed as viable cells measured after 48 hrs by by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 80.78 %)
AID39678Antifungal activity measured against Aspergillus fumigatus1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID1818273Antifungal activity against Aspergillus fumigatus KM8001 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID74301In vivo antifungal activity by topical treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes at a dose of 0.5%1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1658360Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring unknown sterol content at 4 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 2.1%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1818270Antifungal activity against Candida glabrata ATCC 0001 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1658354Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring increase in squalene content at 0.5 ug/ml incubated for 16 hrs by LC-MS analysis relative to control2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1658359Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring unknown sterol content at 0.5 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 2.1%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1728459Antifungal activity against Candida krusei ATCC 6258 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1888307Antifungal activity against fluconazole resistant Candida albicans strain 103 assessed as fungal growth inhibition measured after 72 hrs in presence of miconazole by CLSI protocol based liquid medium dilution method
AID1728461Antifungal activity against Aspergillus fumigatus KM8001 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1658356Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring eburicol content at 0.5 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 1.2%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID74303In vivo antifungal activity by topical treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes at a dose of 2%1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID1888286Drug uptake in fluconazole resistant Candida albicans strain 901 in presence of miconazole by fluorescence microscopy
AID1888284Antifungal activity against fluconazole resistant Candida albicans strain 901 assessed as decrease in fungal cell density in presence of miconazole by fluorescence microscopy
AID1888277Inhibition of SE in Candida albicans ATCC SC5314 incubated for 30 mins using squalene as substrate in presence of NADPH by spectrophotometer analysis
AID74138Compound was evaluated in vivo for the activity (% mycological cure) by topical treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes (0.125% of compound)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID74139Compound was evaluated in vivo for the activity (% mycological cure) by topical treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes (0.5% of compound)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1888262Antifungal activity against Aspergillus fumigatus KM8001 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID125809Antifungal activity against Microsporum canis1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1728457Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1818288Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as squalene level incubated for 48 hrs by LC/MS analysis
AID204474In vitro minimum inhibitory concentration (MIC) against isolates of Sporothrix schenck ii in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1888270Induction of apoptosis in Candida albicans ATCC SC5314 cells assessed as necrotic cells at 8 ug/ml incubated for 72 hrs by Annexin V-FITC/PI staining based flow cytometry method (Rvb = 3.76%)
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID70076Antifungal activity against Epidermophyton floccosum.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID122903In vitro minimum inhibitory concentration (MIC) against isolates of Microsporum canis in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1888258Antifungal activity against Candida albicans ATCC 10231 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1818287Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as ergosterol level incubated for 48 hrs by LC/MS analysis (Rvb = 91.7 %)
AID1818278Antifungal activity against Candida albicans strain 904 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID74300In vivo antifungal activity by topical treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes at a dose of 0.1%1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID1742132Antifungal activity against fluconazole-resistant Candida albicans CaR assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID47882In vitro minimum inhibitory concentration (MIC) against isolates of Candida parapsilosis in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1728496Inhibition of SE in Candida albicans ATCC SC5314 assessed as squalene level at 0.125 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1728500Inhibition of SE in Candida albicans ATCC SC5314 assessed as lanosterol level at 0.5 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1728499Inhibition of SE in Candida albicans ATCC SC5314 assessed as lanosterol level at 0.125 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1742131Antifungal activity against fluconazole-resistant Candida albicans 17# assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1728498Inhibition of SE in Candida albicans ATCC SC5314 assessed as squalene level at 4 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1658338Antifungal activity against Aspergillus fumigatus KM8001 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1742130Antifungal activity against Candida tropicalis assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1888264Antifungal activity against fluconazole resistant Candida albicans strain CaR assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1658334Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1658342Antifungal activity against fluconazole-resistant Candida albicans 632 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1888261Antifungal activity against Candida tropicalis ATCC 1369 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1728503Inhibition of SE in Candida albicans ATCC SC5314 assessed as eburicol level at 0.5 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 1.4 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1742133Antifungal activity against fluconazole-resistant Candida albicans 632 assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1658337Antifungal activity against Candida krusei ATCC 6258 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1888268Induction of apoptosis in Candida albicans ATCC SC5314 cells assessed as live cells at 8 ug/ml incubated for 72 hrs by Annexin V-FITC/PI staining based flow cytometry method (Rvb = 95.56%)
AID1818276Antifungal activity against Candida albicans strain 632 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID1818290Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as eburicol level incubated for 48 hrs by LC/MS analysis (Rvb = 2.8 %)
AID1742153Inhibition of SE in Candida albicans ATCC SC5314 assessed as squalene level at 4 ug/ml incubated for 16 hrs by LC/MS analysis (Rvb = 2.25 %)2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1728493Inhibition of SE in Candida albicans ATCC SC5314 assessed as ergosterol level at 0.125 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 95.1 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1728494Inhibition of SE in Candida albicans ATCC SC5314 assessed as ergosterol level at 0.5 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 95.1 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1742152Inhibition of SE in Candida albicans ATCC SC5314 assessed as eburicol level at 4 ug/ml incubated for 16 hrs by LC/MS analysis (Rvb = 4.67 %)2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID39694In vitro antifungal activity against Aspergillus fumigatus1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID1658351Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring ergosterol content at 0.5 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 96.7%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1888276Antifungal activity against Candida albicans ATCC SC5314 assessed as change in unknown sterol level at 4 ug/ml incubated for 48 hrs by LC-MS analysis (Rvb = 4.3%)
AID1728506Inhibition of SE in Candida albicans ATCC SC5314 assessed as unknown sterol level at 0.5 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 3.5 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888260Antifungal activity against Candida glabrata ATCC 0001 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1658336Antifungal activity against Candida glabrata ATCC 0001 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID204472Antifungal activity measured against Sporothrix schenck ii.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID1818275Antifungal activity against Candida albicans strain CaR assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID278213Increased sensitivity to growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pL37P allele after 24 hrs relative to wild type at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID1658343Antifungal activity against fluconazole-resistant Candida albicans 904 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1658340Antifungal activity against fluconazole-resistant Candida albicans 17# assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1888275Antifungal activity against Candida albicans ATCC SC5314 assessed as change in eburicol level at 4 ug/ml incubated for 48 hrs by LC-MS analysis (Rvb = 1.4%)
AID1728458Antifungal activity against Candida glabrata ATCC 0001 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1658350Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring ergosterol content at 0.125 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 96.7%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1728501Inhibition of SE in Candida albicans ATCC SC5314 assessed as lanosterol level at 4 ug/ml incubated for 48 hrs by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1728466Antifungal activity against fluconazole-resistant Candida albicans 904 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1742128Antifungal activity against Candida glabrata assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1888306Antifungal activity against fluconazole resistant Candida albicans strain 17# assessed as fungal growth inhibition measured after 72 hrs in presence of miconazole by CLSI protocol based liquid medium dilution method
AID1728507Inhibition of SE in Candida albicans ATCC SC5314 assessed as unknown sterol level at 4 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 3.5 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1728467Antifungal activity against Candida albicans ATCC SC5314 assessed as decrease in fungal cell density at 10 nM/mL by polarizing microscopy2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888273Antifungal activity against Candida albicans ATCC SC5314 assessed as change in squalene level at 4 ug/ml incubated for 48 hrs by LC-MS analysis
AID1742154Inhibition of SE in Candida albicans ATCC SC5314 assessed as unidentified sterol level at 4 ug/ml incubated for 16 hrs by LC/MS analysis (Rvb = 7.03 %)2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID214107In vitro minimum inhibitory concentration (MIC) against isolates of Trichophyton mentagrophytes in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID214261In vitro antifungal activity against Trichophyton mentagrophytes1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID1658341Antifungal activity against fluconazole-resistant Candida albicans 901 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1728463Antifungal activity against fluconazole-resistant Candida albicans CaR assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888267Antifungal activity against fluconazole resistant Candida albicans strain 904 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID204346In vitro antifungal activity against Sporothrix schenck ii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID1818291Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as unknown sterol level incubated for 48 hrs by LC/MS analysis (Rvb = 4.3 %)
AID1818283Induction of apoptosis against Candida albicans ATCC SC5314 assessed as late apoptotic cells measured after 48 hrs by by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.71 %)
AID1658339Antifungal activity against fluconazole-resistant Candida albicans CaR assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1888263Antifungal activity against fluconazole resistant Candida albicans strain 17# assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1818269Antifungal activity against Candida albicans SC5314 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID278214Increased sensitivity to growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pR269G allele after 24 hrs relative to wild type at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID1728504Inhibition of SE in Candida albicans ATCC SC5314 assessed as eburicol level at 4 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 1.4 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1658355Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring increase in squalene content at 4 ug/ml incubated for 16 hrs by LC-MS analysis relative to control2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1888266Antifungal activity against fluconazole resistant Candida albicans strain 901 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1888305Antifungal activity against fluconazole resistant Candida albicans strain CaR assessed as fungal growth inhibition measured after 72 hrs in presence of miconazole by CLSI protocol based liquid medium dilution method
AID1818277Antifungal activity against Candida albicans strain 901 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID1728462Antifungal activity against fluconazole-resistant Candida albicans 17# assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1818272Antifungal activity against Candida tropicalis ATCC 1369 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID1742151Inhibition of SE in Candida albicans ATCC SC5314 assessed as lanosterol level at 4 ug/ml incubated for 16 hrs by LC/MS analysis (Rvb = 6.62 %)2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1728505Inhibition of SE in Candida albicans ATCC SC5314 assessed as unknown sterol level at 0.125 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 3.5 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888259Antifungal activity against Candida krusei ATCC 6258 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1728495Inhibition of SE in Candida albicans ATCC SC5314 assessed as ergosterol level at 4 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 95.1 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1888269Induction of apoptosis in Candida albicans ATCC SC5314 cells assessed as early apoptotic cells at 8 ug/ml incubated for 72 hrs by Annexin V-FITC/PI staining based flow cytometry method (Rvb = 0.56%)
AID1888265Antifungal activity against fluconazole resistant Candida albicans strain 103 assessed as fungal growth inhibition measured after 72 hrs by CLSI protocol based liquid medium dilution method
AID1728469Antifungal activity against Candida albicans ATCC SC5314 assessed as induction of cell fracture at 10 nM/mL by polarizing microscopy2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1818271Antifungal activity against Candida krusei ATCC 6258 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID1742134Antifungal activity against fluconazole-resistant Candida albicans 901 assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1728502Inhibition of SE in Candida albicans ATCC SC5314 assessed as eburicol level at 0.125 ug/ml incubated for 48 hrs by LC/MS analysis (Rvb = 1.4 %)2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1818281Induction of apoptosis against Candida albicans ATCC SC5314 assessed as mild apoptotic cells measured after 48 hrs by by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb =0.29 %)
AID214295Antifungal activity against Trichophyton mentagrophytes.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics.
AID1742129Antifungal activity against Aspergillus fumigatus assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1818282Induction of apoptosis against Candida albicans ATCC SC5314 assessed as necrotic cells measured after 48 hrs by by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 18.22 %)
AID1888309Antifungal activity against fluconazole resistant Candida albicans strain 904 assessed as fungal growth inhibition measured after 72 hrs in presence of miconazole by CLSI protocol based liquid medium dilution method
AID125937In vitro antifungal activity against Microsporum canis1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID1658357Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring eburicol content at 4 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 1.2%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1742135Antifungal activity against fluconazole-resistant Candida albicans 904 assessed as inhibition of microbial growth by two fold broth microdilution method2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1888272Antifungal activity against Candida albicans ATCC SC5314 assessed as decrease in ergosterol content at 4 ug/ml incubated for 48 hrs by LC-MS analysis (Rvb = 90.6%)
AID1742136Antifungal activity against Candida albicans ATCC SC5314 assessed as decrease in fungal cell density by polarizing microscopy2020European journal of medicinal chemistry, Nov-01, Volume: 205Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
AID1728465Antifungal activity against fluconazole-resistant Candida albicans 901 assessed as inhibition of microbial growth by NCCLS protocol based method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
AID1658353Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring increase in squalene content at 0.125 ug/ml incubated for 16 hrs by LC-MS analysis relative to control2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1658335Antifungal activity against Candida tropicalis ATCC 1369 assessed as reduction in fungal growth by NCCLS method2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1658358Inhibition of SE in Candida albicans ATCC SC5314 assessed as inhibition of ergosterol biosynthesis by measuring unknown sterol content at 0.125 ug/ml incubated for 16 hrs by LC-MS analysis (Rvb = 2.1%)2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
AID1818274Antifungal activity against Candida albicans strain 17 assessed as reduction in fungal growth incubated for 72 hrs by CLSI protocol based broth microdilution method
AID1888271Induction of apoptosis in Candida albicans ATCC SC5314 cells assessed as late apoptotic cells at 8 ug/ml incubated for 72 hrs by Annexin V-FITC/PI staining based flow cytometry method (Rvb = 0.12%)
AID74020Compound was evaluated in vivo for the activity (% mycological cure) by oral treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes. Dose = 150 mg/kg/day1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-199047 (33.81)18.7374
1990's34 (24.46)18.2507
2000's16 (11.51)29.6817
2010's30 (21.58)24.3611
2020's12 (8.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.43 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index121.64 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (70.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (24.49%)5.53%
Reviews19 (12.93%)6.00%
Case Studies11 (7.48%)4.05%
Observational0 (0.00%)0.25%
Other81 (55.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis. [NCT01580891]Phase 11,053 participants (Actual)Interventional2012-05-31Completed
A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2%and the Naftin® Cream 2% in Patients With Tinea Pedis [NCT02132260]Phase 1890 participants (Actual)Interventional2013-08-31Completed
A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints [NCT02633813]Phase 3693 participants (Actual)Interventional2015-03-31Completed
Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium. [NCT00253305]Phase 275 participants Interventional2005-09-30Completed
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis [NCT01290341]Phase 3860 participants (Actual)Interventional2011-02-28Completed
A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years [NCT02658292]Phase 20 participants (Actual)InterventionalWithdrawn
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis [NCT02466867]Phase 427 participants (Actual)Interventional2014-01-31Completed
An Open Label, Parallel Group Comparison Study To Evaluate the Safety Tolerability, and Pharmacokinetics of UHE-103 Cream Versus Naftin Cream in Subjects With Tinea Cruris and/or Tinea Pedis Under Maximal Use Conditions [NCT05363449]Phase 140 participants (Anticipated)Interventional2022-02-17Recruiting
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis [NCT01712360]Phase 456 participants (Actual)Interventional2012-10-31Completed
A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis. [NCT02335255]Phase 11,519 participants (Actual)Interventional2014-06-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01290341 (2) [back to overview]Complete Cure of Interdigital Tinea Pedis
NCT01290341 (2) [back to overview]Effective Treatment and Mycological Cure of Interdigital Tinea Pedis at Week 6
NCT01712360 (4) [back to overview]Efficacy Variables
NCT01712360 (4) [back to overview]Efficacy Variables
NCT01712360 (4) [back to overview]Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose
NCT01712360 (4) [back to overview]Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose

Complete Cure of Interdigital Tinea Pedis

"The primary efficacy comparison between NAFT-600 gel and placebo will be based on the percentage of subjects at Week 6 with complete cure of interdigital tinea pedis.~Complete cure is defined as negative mycology results (dermatophyte culture and KOH) and the absence of erythema, scaling, and pruritus." (NCT01290341)
Timeframe: Visit 4/ Week 6

Interventionpercentage of subjects (Number)
NAFT-60026.0
Placebo3.3

[back to top]

Effective Treatment and Mycological Cure of Interdigital Tinea Pedis at Week 6

"Effective treatment of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture and erythema, scaling, and pruritus scores of 0 or 1 (corresponding to absent and mild respectively).~Mycological cure of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture." (NCT01290341)
Timeframe: Visit 4/ Week 6

,
Interventionpercentage of subjects (Number)
Mycological CureEffective Treatment
NAFT-60058.850.8
Placebo10.37.0

[back to top]

Efficacy Variables

"Efficacy variables to be analyzed after 2 weeks of once daily application of both products (NAFT-500 or NAFT-600).~Efficacy variables to be analyzed:~- Subject satisfaction" (NCT01712360)
Timeframe: Day 28

,,,,,
InterventionPercentage (%) of subjects (Number)
Excellent ImprovementMuch ImprovedImprovedNo ChangeWorse
NAFT500 (Adult, Foot)083.316.700
NAFT500 (Adult, Groin)16.750.033.300
NAFT500 (Pediatric, Foot)81.813.64.500
NAFT500 (Pediatric, Groin)86.413.6000
NAFT600 (Adult)20.060.020.000
NAFT600 (Pediatric)54.536.44.500

[back to top]

Efficacy Variables

"Efficacy variables to be analyzed after 2 weeks of once daily application of both products (NAFT-500 or NAFT-600).~Efficacy variables to be analyzed:~Complete cure~Treatment effectiveness~Mycological cure~Clinical success~Clinical cure" (NCT01712360)
Timeframe: Day 28

,,,,,
InterventionPercentage (%) of subjects (90% CI) (Number)
Complete CureTreatment EffectivenessMycological CureClinical SuccessClinical Cure
NAFT500 (Adult, Foot)0016.766.716.7
NAFT500 (Adult, Groin)16.750.066.766.733.3
NAFT500 (Pediatric, Foot)59.163.668.290.981.8
NAFT500 (Pediatric, Groin)63.663.672.790.981.8
NAFT600 (Adult)020.020.08020.0
NAFT600 (Pediatric)27.354.563.681.840.9

[back to top]

Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose

"Variables will be derived from naftifine plasma concentration at day 1. Variables to be analyzed:~- Maximum observed plasma concentration (Cmax): the highest plasma concentration in each subject after single dose.~Variables will be derived from naftifine plasma concentration at day 14. Variables to be analyzed:~- Maximum observed plasma concentration (Cmax): the highest plasma concentration in each subject at steady state (SS)." (NCT01712360)
Timeframe: Day 1 and Day 14

,,,
Interventionpg/mL (Geometric Mean)
Cmax Day 1, Single DoseCmax, SS Day 14 Multiple Dose
NAFT500 (Adult)3983.346826.70
NAFT500 (Pediatric)9213.3512727.36
NAFT600 (Adult)1741.023538.84
NAFT600 (Pediatric)1397.773813.38

[back to top]

Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose

"Variables will be derived from naftifine plasma concentration at day 1. Variables to be analyzed:~- Partial area under the plasma concentration-time curve (0-24 hours postdose) (AUC), as calculated using the linear trapezoid rule.~Variables will be derived from naftifine plasma concentration at day 14. Variables to be analyzed:~- Area under the plasma concentration-time curve (AUC) within one dosing interval at steady state (SS). AUCτ,ss= Area under the concentration curve within a dosing interval (τ = 24 hours) at steady state" (NCT01712360)
Timeframe: Day 1 and Day 14

,,,
Interventionh*pg/mL (Geometric Mean)
AUC0-24 Day 1, Single DoseAUCτ,ss Day 14 Multiple Dose
NAFT500 (Adult)68634.2124596.0
NAFT500 (Pediatric)138262.2192485.4
NAFT600 (Adult)17213.972849.8
NAFT600 (Pediatric)15890.160038.5

[back to top]